Valuation: MediciNova, Inc.

Market Cap 65.96M 57.05M 53.28M 48.88M 91.93M 6.28B 93.39M 625M 245M 3.15B 248M 242M 10.4B P/E 2026 *
-5.15x
P/E 2027 * -3.57x
Enterprise Value 65.96M 57.05M 53.28M 48.88M 91.93M 6.28B 93.39M 625M 245M 3.15B 248M 242M 10.4B EV / Sales 2026 *
149x
EV / Sales 2027 * 165x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
07-15 Medicinova Achieves Target Enrollment in Seanobi-Als Study Evaluating Mn-166 in Als Patients CI
06-08 MediciNova Receives Notice Of Allowance For New Patent Covering Use Of MN-166 In Combination With Anti-PD-1 Immune Checkpoint Inhibitor For Glioblastoma Treatment CI
06-08 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT
05-27 MediciNova Announces Completion Of Last Patient Last Visit In The MN-001-NATG-202 Clinical Trial Of MN-001 CI
05-14 MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-16 HC Wainwright Initiates MediciNova at Buy With $10 Price Target MT
02-20 MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-30 MediciNova, Inc. Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access- Program Evaluating MN-166 in ALS Patients CI
12-30 MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets RE
12-18 MediciNova, Inc. Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
12-18 MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug MT
12-08 MediciNova, Inc. Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 in ALS (COMBAT-ALS) in ALS Presented at the 36th International Symposium on ALS/MND CI
11-19 MediciNova, Inc. Appoints Dr. Christopher Breder, MD, Phd as Clinical and Regulatory Advisorand to Lead Scientific Advisory Board Upon Its Formation CI
1 day-1.47%
1 week+0.75%
Current month+0.75%
1 month-6.94%
3 months-6.29%
6 months-16.25%
Current year+2.29%
1 week 1.3
Extreme 1.3
1.39
1 month 1.28
Extreme 1.28
1.43
Current year 1.22
Extreme 1.22
1.92
1 year 1.17
Extreme 1.168
1.96
3 years 1.12
Extreme 1.12
2.55
5 years 1.12
Extreme 1.12
4.65
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 31/07/2005
Director of Finance/CFO 49 15/06/2022
Chief Tech/Sci/R&D Officer 60 31/08/2011
Director TitleAgeSince
Chairman 76 25/09/2000
Director/Board Member 60 23/07/2019
Director/Board Member 69 31/08/2004
Date Insider Type Main position Quantity % Market Cap.
16/01/26 Free

Chief Executive Officer

450,000 0.9156%
16/01/26 Free

Chief Technology Officer

350,000 0.7122%
17/06/25 Free

Director

20,000 0.0408%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%+0.75%-2.19%-45.31% 65.96M
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.31%+10.59%+47.40%+181.76% 26.36B
Weighted average by Cap. +4.36%+13.09%+49.47%+168.44%

Financials

2026 *2027 *
Net sales 444K 384K 358K 329K 618K 42.21M 628K 4.2M 1.65M 21.16M 1.67M 1.63M 69.94M 400K 346K 323K 296K 558K 38.07M 566K 3.79M 1.49M 19.08M 1.5M 1.47M 63.08M
Net income -13.5M -11.68M -10.91M -10.01M -18.82M -1.29B -19.12M -128M -50.22M -644M -50.7M -49.59M -2.13B -22.14M -19.15M -17.89M -16.41M -30.86M -2.11B -31.35M -210M -82.36M -1.06B -83.14M -81.32M -3.49B
Net Debt - -
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
07/08/26 US$1.340 -1.47% 11,384
06/08/26 US$1.360 +2.26% 18,667
05/08/26 US$1.330 +2.31% 13,758
04/08/26 US$1.300 -2.26% 82,925
03/08/26 US$1.330 0.00% 39,190
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.340USD
Average target price
9.000USD
Spread / Average Target
+571.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNOV Stock